Phage Therapy Market to Grow by USD 51 Million (2024-2028), Vendor Strategies Boost Growth, AI-Powered Market Evolution Report - Technavio

The global phage therapy market is set for growth, projected to reach USD 51 million by 2028, driven by a CAGR of 17.41% from 2023. Bacteriophage therapy is revolutionizing the fight against bacterial infections, with applications extending to human healthcare, agriculture, and industrial biotechnology. The increasing number of phage therapy clinical trials is fueling extensive research into therapeutic applications, safety standards, treatment efficacy, and possible side effects. Furthermore, advancements in phage therapy manufacturing techniques and evolving regulatory guidelines are shaping the market landscape. This report provides an in-depth analysis of emerging market trends, breakthroughs in research and development, and future opportunities within the rapidly expanding phage therapy industry.Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Market Segmentation

By Product

• Escherichia coli

• Staphylococcus aureus

• Salmonella

• Others

By Application

• Animal Health

• Food Industry

By Region

North America

• The U.S.

• Canada

Europe

• U.K.

• Germany

• France

• Rest of Europe

Asia

• China

• India

Rest of World (ROW)

• Brazil

• Argentina

• Australia

Europe, contributing 34% to global market growth, benefits from a well-developed healthcare infrastructure and government support for research. Countries like Germany and the U.K. are key contributors. High tuberculosis detection rates in 2023 have increased the adoption of bacteriophage therapy for multidrug-resistant TB.

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Dynamics

Key Drivers

Increasing phage therapy clinical trials for animal health is a major driver. Cytophage Technologies is developing bacteriophages to replace antibiotics in livestock. The Canadian government has introduced new legislation restricting antibiotic use in food production, fueling demand for bacteriophage therapy.

Emerging Trends

Growing interest in phage therapy clinical trials is revitalizing the market. Advances in high-throughput sequencing, genetic engineering, and synthetic biology are overcoming past limitations. In November 2023, BiomX reported positive results from Phase 2 trials of BX004, an inhaled bacteriophage therapy for Pseudomonas aeruginosa lung infections. The treatment will advance to Phase 2b/3, pending funding and regulatory approval.

Challenges

Stringent regulations on phage therapy pose a significant challenge. Regulatory frameworks in the U.S. and EU classify phages as biological materials, requiring extensive safety, efficacy, and manufacturing compliance. High costs associated with GMP requirements limit market accessibility for hospitals and research centers.

Discover how AI is revolutionizing market trends- Get your access now!

Key Market Players

• Adaptive Phage Therapeutics

• APS Biocontrol Ltd.

• Armata Pharmaceuticals Inc.

• Astellas Pharma Inc.

• BiomX Inc.

• CJ CheilJedang Corp.

• Cytophage Technologies Inc.

• Eliava Biopreparation LLC

• Intralytix Inc.

• iNtRON Biotechnology Inc.

• JSC NPO Microgen

• Locus Biosciences Inc.

• Micreos

• Micromir

• Nexabiome

• Proteon Pharmaceuticals S.A.

• Taconic Biosciences Inc.

• TechnoPhage

• ZeptoMetrix LLC

• Vitalis Wellness LLP

Future Insights

With increasing antibiotic resistance and regulatory advancements, bacteriophage therapy is expected to see expanded clinical applications. Investment in phage therapy clinical trials, improved manufacturing methods of phage therapy, and enhanced regulations on phage therapy will drive market growth through 2028